Intended for healthcare professionals


Effective ovarian cancer treatment is underused, US study finds

BMJ 2015; 351 doi: (Published 06 August 2015) Cite this as: BMJ 2015;351:h4291
  1. Michael McCarthy
  1. 1Seattle

Six years after the US National Cancer Institute issued a special clinical announcement encouraging the use of intraperitoneal and intravenous chemotherapy for ovarian cancer, less than half of eligible women were being treated with it, a new study has found.1

The institute issued the recommendation in 2006 after a randomized trial by the Gynecologic Oncology Group, the GOG-172 trial, showed that, when compared with intravenous chemotherapy alone, intraperitoneal and intravenous chemotherapy was associated with an improvement of 16 months in median overall survival among women with optimally …

View Full Text

Log in

Log in through your institution


* For online subscription